Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention.

@article{Oshea2002LongtermEO,
  title={Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention.},
  author={J Conor O'shea and Christopher E H Buller and Warren J. Cantor and A. Bleakley Chandler and Eric A Cohen and David Jacques Cohen and Ian C Gilchrist and Neal S. Kleiman and Marino Labinaz and Mina Madan and Gail E. Hafley and Robert M. Califf and Michael M. Kitt and John T. Strony and James E. Tcheng},
  journal={JAMA},
  year={2002},
  volume={287 5},
  pages={618-21}
}
CONTEXT In the Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) trial, treatment with eptifibatide, a platelet glycoprotein IIb/IIIa integrin blocker, was found to reduce the ischemic complications of nonurgent coronary stent implantation at 48 hours and 30 days. OBJECTIVE To determine whether eptifibatide treatment continues to provide durable, long-term benefit after coronary stent intervention. DESIGN AND SETTING The ESPRIT trial was a randomized… CONTINUE READING